All News

The trend is strong, bold ideas that travel across cultures.

With so much variation, why force local affiliates to use the global agency?This is a battle seldom worth the fight.

We need to start thinking of digital as part of a marketing plan instead of The Plan.

An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.

To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.

Sure, there might be a few key audiences whose view of your reputation is critical, but targeting them is fairly simple and often inexpensive. More times than not, it's better to keep your head down than raise the banner and lead the field.

Hot topics in the pharma advertising world and covered in this year's Agency Confidential include marketing drugs in emerging countries, and why you shouldn't worry about what people say about your company.

Two of the most essential supplies we can offer emerging regions are infrastructure support and easier access to health information

Independence equals creativity, and solutions

Strategy-listening, seeing, thinking-all need to be done locally.

New high-growth markets are reflecting an unprecedented shift of industry growth to the world's emerging economies. How are Pharma's agencies coping?

The monolithic dictates out of marketing and agency headquarters in New York and London-and the way they are forced on local marketing efforts-work to undermine adoption at the local level

A global agency has the highest chance of ensuring core brand value

In China people view expenditures on pharmaceuticals as a "cost" rather than a "purchase"

The pharma industry has only recently seen the kinds of price pressures that the retail industry has operated under for decades.

The companies with the best corporate reputations have responsibility initiatives that earn their way, but very few of them started in response to a perceived problem or a bit of bad press.

After an active campaign spanning nearly six years, the epidemiology data showed a decline in the number of patients with Hep B, from 1.3 million to 0.9 million.

Emerging Pharma Leaders

The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.

Social networking helps sponsors drive clinical trials recruitment.

Pharma companies can maximize partnership benefits with social media.

Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"

December 2009 BPA Statement

May 24, 2010.

In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results

One Pill Makes You Better?

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.

A new Cegedim Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job.

After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?